Clinical trials have demonstrated Ang II effectively increased blood pressure and may have benefits to AKI patients with renal replacement in vasodilatory shock, but no benefits for preventing early-stage SIAKI deterioration (33–35). The gene discussed is AGT; the disease is acute kidney injury.